Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in exacerbations requiring steroids, antibiotics or both compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to lower hospital admissions due to exacerbations compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes exacerbations requiring steroids, antibiotics or both compared with tiotropium (very low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events at study endpoint · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).
2 findings from 1 review
OR 0.98 [0.75, 1.3]
890 participants
Low
OR 0.82 [0.62, 1.09]
894 participants
Low
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).
1 finding from 1 review
Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review